H. Lundbeck Gelecekteki Büyüme
Future kriter kontrolleri 0/6
H. Lundbeck 'in gelir ve kazançlarının sırasıyla yıllık 3.4% ve 4.6% oranında düşmesi öngörülüyor. EPS'nin yıllık 3.8% oranında düşüşmesi bekleniyor. Öz sermaye getirisinin 3 yıl içinde 13.3% olması öngörülüyor.
Anahtar bilgiler
-4.6%
Kazanç büyüme oranı
-3.83%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 10.7% |
| Gelir büyüme oranı | -3.4% |
| Gelecekteki özkaynak getirisi | 13.26% |
| Analist kapsamı | Good |
| Son güncelleme | 30 Jun 2026 |
Gelecekteki son büyüme güncellemeleri
Analiz Makalesi • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...Analiz Makalesi • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...Analiz Makalesi • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...Analiz Makalesi • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...Recent updates
Anlatı Güncellemesi • Jun 22
HLUN B: Neuroscience Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their fair value estimate for H. Lundbeck at DKK 47.21.Analiz Makalesi • Jun 18
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
Anlatı Güncellemesi • Jun 06
HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple
Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.Analiz Makalesi • May 24
H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively
H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Anlatı Güncellemesi • May 23
HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside
Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.Analiz Makalesi • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Anlatı Güncellemesi • May 05
HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins
Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.Anlatı Güncellemesi • Apr 20
HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook
Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.Anlatı Güncellemesi • Apr 05
HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins
Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.Anlatı Güncellemesi • Mar 22
HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion
Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.Anlatı Güncellemesi • Mar 08
HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential
Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.Anlatı Güncellemesi • Feb 22
HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook
Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.Anlatı Güncellemesi • Feb 08
HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares
Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.Analiz Makalesi • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...Anlatı Güncellemesi • Jan 25
HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook
Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.Analiz Makalesi • Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Anlatı Güncellemesi • Jan 11
HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook
Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.Anlatı Güncellemesi • Dec 27
HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements
Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.Anlatı Güncellemesi • Dec 13
HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares
Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.Analiz Makalesi • Nov 22
The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business
H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...Analiz Makalesi • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...Analiz Makalesi • Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...Anlatı Güncellemesi • Sep 05
CNS Pipeline And Global Expansion Will Unlock Future Opportunities
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.Analiz Makalesi • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
Yeni Anlatı • Dec 04
Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth
Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 25,016 | 4,692 | 5,592 | 6,091 | 10 |
| 12/31/2027 | 25,845 | 4,856 | 6,244 | 6,844 | 11 |
| 12/31/2026 | 25,744 | 4,744 | 5,616 | 6,254 | 11 |
| 3/31/2026 | 25,520 | 3,730 | 4,825 | 5,448 | N/A |
| 12/31/2025 | 24,630 | 3,192 | 4,863 | 5,481 | N/A |
| 9/30/2025 | 24,078 | 3,777 | 2,778 | 3,406 | N/A |
| 6/30/2025 | 23,521 | 3,453 | 2,851 | 3,409 | N/A |
| 3/31/2025 | 22,951 | 3,257 | 2,415 | 2,997 | N/A |
| 12/31/2024 | 22,004 | 3,143 | 2,761 | 3,326 | N/A |
| 9/30/2024 | 21,441 | 2,687 | 4,936 | 5,421 | N/A |
| 6/30/2024 | 20,671 | 2,586 | 4,128 | 4,609 | N/A |
| 3/31/2024 | 20,156 | 2,416 | 4,145 | 4,663 | N/A |
| 12/31/2023 | 19,912 | 2,290 | 3,579 | 4,080 | N/A |
| 9/30/2023 | 19,614 | 2,467 | 3,528 | 4,426 | N/A |
| 6/30/2023 | 19,381 | 2,479 | 3,523 | 4,457 | N/A |
| 3/31/2023 | 18,918 | 2,384 | 3,292 | 4,102 | N/A |
| 12/31/2022 | 18,246 | 1,916 | 2,699 | 3,519 | N/A |
| 9/30/2022 | 17,619 | 1,603 | 2,051 | 2,615 | N/A |
| 6/30/2022 | 16,913 | 1,236 | 1,744 | 2,313 | N/A |
| 3/31/2022 | 16,398 | 1,109 | 1,344 | 1,959 | N/A |
| 12/31/2021 | 16,299 | 1,318 | 1,660 | 2,272 | N/A |
| 9/30/2021 | 16,521 | 1,873 | 2,405 | 2,949 | N/A |
| 6/30/2021 | 16,971 | 1,965 | 2,379 | 2,912 | N/A |
| 3/31/2021 | 17,381 | 2,110 | 3,263 | 3,757 | N/A |
| 12/31/2020 | 17,672 | 1,581 | 3,359 | 3,837 | N/A |
| 9/30/2020 | 17,818 | 904 | 2,713 | 3,171 | N/A |
| 6/30/2020 | 17,490 | 1,242 | 2,910 | 3,354 | N/A |
| 3/31/2020 | 17,366 | 1,507 | 1,502 | 1,960 | N/A |
| 12/31/2019 | 17,036 | 2,313 | N/A | 2,609 | N/A |
| 9/30/2019 | 16,811 | 3,091 | N/A | 3,621 | N/A |
| 6/30/2019 | 17,309 | 3,395 | N/A | 3,462 | N/A |
| 3/31/2019 | 17,766 | 3,606 | N/A | 4,815 | N/A |
| 12/31/2018 | 18,117 | 3,907 | N/A | 5,981 | N/A |
| 9/30/2018 | 18,313 | 3,806 | N/A | 5,922 | N/A |
| 6/30/2018 | 18,028 | 3,627 | N/A | 6,197 | N/A |
| 3/31/2018 | 17,608 | 3,236 | N/A | 5,397 | N/A |
| 12/31/2017 | 17,234 | 2,624 | N/A | 4,045 | N/A |
| 9/30/2017 | 17,007 | 2,544 | N/A | 3,731 | N/A |
| 6/30/2017 | 16,607 | 1,988 | N/A | 3,551 | N/A |
| 3/31/2017 | 16,075 | 1,612 | N/A | 3,420 | N/A |
| 12/31/2016 | 15,634 | 1,211 | N/A | 3,126 | N/A |
| 9/30/2016 | 15,202 | 290 | N/A | 4,158 | N/A |
| 6/30/2016 | 14,923 | -1,289 | N/A | 2,755 | N/A |
| 3/31/2016 | 14,801 | -5,427 | N/A | 936 | N/A |
| 12/31/2015 | 14,594 | -5,694 | N/A | 197 | N/A |
| 9/30/2015 | 14,108 | -5,879 | N/A | -1,330 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: HLUN B şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -4.6% ).
Kazançlar ve Piyasa: HLUN B şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -4.6% ).
Yüksek Büyüme Kazançları: HLUN B şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.
Gelir ve Pazar: HLUN B şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -3.4% ).
Yüksek Büyüme Geliri: HLUN B şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -3.4% ).
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: HLUN B 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.3 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/01 01:41 |
| Gün Sonu Hisse Fiyatı | 2026/07/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
H. Lundbeck A/S 34 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rosie Turner | Barclays |
| Charles Pitman | Barclays |
| Emily Field | Barclays |